Prescient Therapeutics (ASX:PTX) to showcase CellPryme and OmniCAR data at ISCT event in Paris

Highlights

• OmniCAR and CellPryme abstracts of Prescient have been accepted for showcasing at the annual meeting of the prestigious International Society of Cell & Gene Therapy (ISCT)
• The two abstracts would also be published in the next issue of ISCT’s official journal Cytotherapy
• Prescient's CEO lauded the development as the "testament to the quality and novelty" of the company’s science

Prescient Therapeutics (ASX: PTX) -- a publicly listed oncology company developing targeted and cell therapies -- has informed that the International Society of Cell & Gene Therapy (ISCT) has accepted two Prescient abstracts, OmniCAR and CellPryme, to be showcased at the annual meeting in Paris, France. The two selected abstracts would also find place in the official journal of ISCT. 

The event, scheduled between 31 May and 3 June this year, will witness participation by clinicians, researchers, regulators and other stakeholders of the cell and gene therapy space.

PTX shares jump 

PTX shares jumped over 3.5% to trade at AU$0.088 at the time of writing on 16 May 2023.

More

Prescient Therapeutics' OmniCAR (a controllable CAR platform), alongside PTX's CellPryme (a cell therapy enhancement platform) have been approved by the ISCT for presentation at the annual meeting to be held in Paris, France. PTX researchers would use the event to showcase new preclinical data on the two abstracts. Additionally, the abstracts would find place in Cytotherapy's (ISCT's official journal) next publication.

The ISCT event is a prestigious platform that counts clinicians, regulators and other relevant stakeholders from the cell and gene therapy field as attendees. ISCT is said to be a global leader in pre-clinical and translational aspects of cell and gene therapeutics development. It supports advancement of scientific research into innovative treatments. The annual event brings together over 2,700 experts from 60 countries, working in the cell and gene therapy space.

Notably, Prescient is an ASX-listed oncology company, and its targeted therapies include PTX-100 and PTX-200, with the former holding the Orphan Drug Designation (all T cell lymphomas) from the Food and Drug Administration (US). OmniCAR, and CellPryme-M and CellPryme-A are the cell therapies of Prescient.

Statement by PTX CEO and Managing Director

Steven Yatomi-Clarke has lauded the inclusion of OmniCAR and CellPryme abstracts in the prestigious annual ISCT conference to be held in France. He commented that this development is "testament to the quality and novelty" of Prescient's science.